{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-25-010579","form_type":"8-K","ticker":"ZIVO","cik":"0001101026","company_name":"Zivo Bioscience, Inc.","filed_at":"2025-09-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.342739+00:00","generated_at":"2026-05-17T06:57:23.921090+00:00","sec_items":["7.01","9.01"],"event_type":"other","sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"medium","headline":"ZIVO CEO letter highlights algae antioxidant validation and animal health progress","bullets":["Independent analysis showed ZIVO's algae has nearly double SOD activity vs. a competing algae product.","Poultry avian influenza study: treated birds showed delayed transmission, lower viral shedding, faster immune response.","Management and board personally invested in the Company, signaling conviction in undervalued stock.","Company targets $4.5B antibiotic-free feed market growing at 8.2% CAGR through 2033.","CEO acknowledges liquidity challenges but expects near-term revenue from nutraceutical commitments."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-25-010579","json":"https://secwatch.observer/filing/0001654954-25-010579.json","markdown":"https://secwatch.observer/filing/0001654954-25-010579.md","text":"https://secwatch.observer/filing/0001654954-25-010579.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1101026/000165495425010579/0001654954-25-010579-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1101026/000165495425010579/zivo_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:57:23.921090+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}